ArticleNucleic acids research2026
Site-specific ribozyme-mediated alkylation of DNA substrates.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
MTR1 is an in vitro-selected ribozyme that catalyses the transfer of an alkyl group from exogenous O6-alkylguanine to N1 of a specific adenine in RNA. We show here that the ribozyme can also efficiently alkylate a DNA substrate strand, with almost complete alkylation in 20 min. We have determined crystal structures of the products of methyl and benzyl transfer. The structures are closely similar to that of the all-RNA ribozyme, binding the guanine product in an identical manner, and alkylation occurs at the equivalent location as in the RNA, i.e. N1 of dA63. 2'-O-methylation of C10 and U45, which are hydrogen-bonded to the exogenous guanine, leads to an order-of-magnitude faster rate of alkyl transfer. The results indicate that MTR1 could be a useful tool for the site-specific modification of DNA, including the creation of fluorescent labels or targets for chemical crosslinking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.